Clinical decision support improves autoimmune/paraneoplastic antibody panel utilization

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
Robert D Nerenz, Sam I Hooshmand, Eric Jackowiak, David Shirilla, Yushan Yang, Kai Yang, Ahmed Z Obeidat
{"title":"Clinical decision support improves autoimmune/paraneoplastic antibody panel utilization","authors":"Robert D Nerenz, Sam I Hooshmand, Eric Jackowiak, David Shirilla, Yushan Yang, Kai Yang, Ahmed Z Obeidat","doi":"10.1093/ajcp/aqae101","DOIUrl":null,"url":null,"abstract":"Objectives Selection of autoimmune/paraneoplastic antibody panels remains challenging because health-care professionals often lack familiarity with panel contents, recommended specimen types, and antibody combinations for a given patient. Inappropriate use adds cost, prompts unnecessary additional workup, and delays the identification of the true cause of patient symptoms. In this study, we assessed whether order-entry clinical decision support can improve autoimmune/paraneoplastic antibody panel utilization. Methods An order-entry clinical decision support tool was embedded in the electronic health record system. Using a nested panel structure, the decision support tool prompted clinicians to identify their patient’s clinical presentation and guided selection of the appropriate tests. In addition, the tool featured a duplicate checking function to alert clinicians when placing multiple orders with substantially similar antibody content within a 3-month period. Panel ordering practices were assessed during the 12 months before implementation and compared with the 6 months immediately following implementation. Results Clinical decision support significantly reduced the monthly test volume of all orderables from 75.8 per month before implementation to 54.5 per month after implementation (incident rate ratio [IRR], 0.72; 95% CI, 0.63-0.81; P < .001). Placement of multiple orders for panels with substantially overlapping antibody content also decreased significantly, from 7.0 per month to 1.2 per month (IRR, 0.17; 95% CI, 0.07-0.33; P < .001). The number of neural-specific antibodies detected remained unchanged, but the reduction in total test volume increased the neural-specific antibody positivity rate from 4.2% to 6.8% (IRR, 1.61; 95% CI, 0.94-2.70; P = .075). Conclusions Order-entry clinical decision support offers an efficient and effective approach to improve the utilization of autoimmune/paraneoplastic antibody panels.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajcp/aqae101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives Selection of autoimmune/paraneoplastic antibody panels remains challenging because health-care professionals often lack familiarity with panel contents, recommended specimen types, and antibody combinations for a given patient. Inappropriate use adds cost, prompts unnecessary additional workup, and delays the identification of the true cause of patient symptoms. In this study, we assessed whether order-entry clinical decision support can improve autoimmune/paraneoplastic antibody panel utilization. Methods An order-entry clinical decision support tool was embedded in the electronic health record system. Using a nested panel structure, the decision support tool prompted clinicians to identify their patient’s clinical presentation and guided selection of the appropriate tests. In addition, the tool featured a duplicate checking function to alert clinicians when placing multiple orders with substantially similar antibody content within a 3-month period. Panel ordering practices were assessed during the 12 months before implementation and compared with the 6 months immediately following implementation. Results Clinical decision support significantly reduced the monthly test volume of all orderables from 75.8 per month before implementation to 54.5 per month after implementation (incident rate ratio [IRR], 0.72; 95% CI, 0.63-0.81; P < .001). Placement of multiple orders for panels with substantially overlapping antibody content also decreased significantly, from 7.0 per month to 1.2 per month (IRR, 0.17; 95% CI, 0.07-0.33; P < .001). The number of neural-specific antibodies detected remained unchanged, but the reduction in total test volume increased the neural-specific antibody positivity rate from 4.2% to 6.8% (IRR, 1.61; 95% CI, 0.94-2.70; P = .075). Conclusions Order-entry clinical decision support offers an efficient and effective approach to improve the utilization of autoimmune/paraneoplastic antibody panels.
临床决策支持提高了自身免疫/副肿瘤抗体面板的利用率
目标 选择自身免疫/副肿瘤抗体检测板仍然是一项挑战,因为医疗保健专业人员往往不熟悉检测板的内容、推荐的标本类型以及特定患者的抗体组合。使用不当会增加成本,引起不必要的额外检查,并延误患者症状真正原因的鉴定。在本研究中,我们评估了订单输入临床决策支持是否能提高自身免疫/副肿瘤抗体检测板的利用率。方法 在电子病历系统中嵌入订单输入临床决策支持工具。该决策支持工具采用嵌套式面板结构,提示临床医生确定患者的临床表现,并指导选择适当的检测项目。此外,该工具还具有重复检查功能,当临床医生在 3 个月内多次下达抗体内容基本相似的订单时,该工具会发出警报。在实施前的 12 个月中,对专家小组的订购实践进行了评估,并与实施后的 6 个月进行了比较。结果 临床决策支持大大降低了所有订单的月检验量,从实施前的每月 75.8 份降至实施后的每月 54.5 份(事故率比 [IRR],0.72;95% CI,0.63-0.81;P < .001)。对抗体内容基本重叠的检测板进行多次订购的情况也明显减少,从每月 7.0 次降至每月 1.2 次(IRR,0.17;95% CI,0.07-0.33;P &p;lt; .001)。检测到的神经特异性抗体数量保持不变,但检测总量的减少使神经特异性抗体阳性率从 4.2% 上升到 6.8%(IRR,1.61;95% CI,0.94-2.70;P = .075)。结论 订单输入临床决策支持为提高自身免疫/副肿瘤抗体检测的利用率提供了一种高效、有效的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信